-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $60

Benzinga·03/20/2026 20:45:52
Listen to the news
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and raises the price target from $36 to $60.